IDYA
IDEAYA Biosciences, Inc.
Biotechnology · Healthcare · United States
31.96
close · 2026-10-30
value
78
cheaper than peers78
quality
67
stronger fundamentals67
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 3 years ago | -4.4% | 73 |
| cash flow yield, latest year | -2.4% | 72 |
| earnings yield, 2 years ago | -6.1% | 72 |
| cash flow yield, 3 years ago | -2.9% | 69 |
| cash flow yield, 2 years ago | -3.8% | 69 |
| earnings yield, latest year | -4.0% | 66 |
| price to book | 2.57× | 63 |
| earnings yield, 1 year ago | -10.5% | 59 |
| cash flow yield, 1 year ago | -8.2% | 55 |
| price to sales | 13.17× | 47 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 2.4% | 84 |
| return on equity | -16.2% | 75 |
| operating margin | -1380.7% | 18 |
3 of 4 measures available
Facts
| market cap | $3B |
| free cash flow | -$70.8M |
| employees | 145 |
| first trade | 2019-05-23 |
| next earnings | 2026-08-04 |
| fundamentals updated | 2026-08-07 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.28 | -3.36 | -1.96 | -1.42 |
| free cash flow | -$73.5M | -$251.4M | -$117.6M | -$90.6M |
| net income | -$113.7M | -$274.5M | -$113.0M | -$58.7M |
| revenue | $218.7M | $7.0M | $23.4M | $50.9M |